caffeine has been researched along with Palmoplantaris Pustulosis in 13 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Evaluation of the efficacy of topical caffeine 10% in the treatment of psoriasis." | 9.11 | Evaluation of the efficacy of topical caffeine in the treatment of psoriasis vulgaris. ( Asilian, A; Khalesi, E; Khoddami, L; Mohammady, M; Shahtalebi, M; Vali, A, 2005) |
| "Combination of curcumin with anti-inflammatory drug like caffeine shows augmented antipsoriatic action compared to curcumin alone and reduce the time taken for treatment of Psoriasis." | 7.96 | Design & development of nanosponge loaded topical gel of curcumin and caffeine mixture for augmented treatment of psoriasis. ( Balamuralidhara, V; Gupta, NV; Iriventi, P; Osmani, RAM, 2020) |
| "One hundred and fifty patients with diagnoses of psoriasis or psoriatic arthritis were surveyed for their current weekly methotrexate dosage and their usual daily consumption of caffeine." | 7.74 | Caffeine consumption and methotrexate dosing requirement in psoriasis and psoriatic arthritis. ( Barnes, SA; el-Azhary, RA; Mengden Koon, SJ; Swanson, DL, 2007) |
| "Eight patients with psoriasis were given 200 mg caffeine orally with or without 1." | 7.69 | Inhibition of caffeine metabolism by 5-methoxypsoralen in patients with psoriasis. ( Agache, P; Bechtel, PR; Bechtel, Y; Bendriss, A; Bendriss, EK; Humbert, PH; Magnette, J; Paintaud, G, 1996) |
| "Patients with moderate to severe chronic plaque psoriasis (n = 21) received single oral doses of sensitive probe substrates for CYP1A2 (caffeine 100 mg), CYP2C9 (warfarin 10 mg), CYP2C19 (omeprazole 20 mg), CYP2D6 (metoprolol 50 mg), and CYP3A (midazolam 2 mg) on day 1, followed by 12 weeks of subcutaneous risankizumab treatment of 150 mg once every 4 weeks from day 8 to day 92, and again the same cocktail of substrates on day 98." | 5.30 | Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis. ( Camez, A; Cheng, L; Ignatenko, S; Khatri, A; Othman, AA; Pang, Y, 2019) |
| "Evaluation of the efficacy of topical caffeine 10% in the treatment of psoriasis." | 5.11 | Evaluation of the efficacy of topical caffeine in the treatment of psoriasis vulgaris. ( Asilian, A; Khalesi, E; Khoddami, L; Mohammady, M; Shahtalebi, M; Vali, A, 2005) |
| "Combination of curcumin with anti-inflammatory drug like caffeine shows augmented antipsoriatic action compared to curcumin alone and reduce the time taken for treatment of Psoriasis." | 3.96 | Design & development of nanosponge loaded topical gel of curcumin and caffeine mixture for augmented treatment of psoriasis. ( Balamuralidhara, V; Gupta, NV; Iriventi, P; Osmani, RAM, 2020) |
| "One hundred and fifty patients with diagnoses of psoriasis or psoriatic arthritis were surveyed for their current weekly methotrexate dosage and their usual daily consumption of caffeine." | 3.74 | Caffeine consumption and methotrexate dosing requirement in psoriasis and psoriatic arthritis. ( Barnes, SA; el-Azhary, RA; Mengden Koon, SJ; Swanson, DL, 2007) |
| "Eight patients with psoriasis were given 200 mg caffeine orally with or without 1." | 3.69 | Inhibition of caffeine metabolism by 5-methoxypsoralen in patients with psoriasis. ( Agache, P; Bechtel, PR; Bechtel, Y; Bendriss, A; Bendriss, EK; Humbert, PH; Magnette, J; Paintaud, G, 1996) |
| "The acute effect of a single oral dose of methoxsalen on the pharmacokinetics of caffeine was investigated in five nonsmoking volunteers with psoriasis." | 3.67 | Methoxsalen is a potent inhibitor of the metabolism of caffeine in humans. ( Camisa, C; Cheney, P; Gerber, N; Mays, DC; Nawoot, S; Pacula, CM, 1987) |
| " The probe cocktail was generally well-tolerated when administered in combination with guselkumab in patients with psoriasis." | 2.94 | Evaluating Potential Disease-Mediated Protein-Drug Interactions in Patients With Moderate-to-Severe Plaque Psoriasis Receiving Subcutaneous Guselkumab. ( Chen, D; Piantone, A; Sharma, A; Shu, C; Xu, Y; Xu, Z; Zhou, H; Zhu, Y; Zhuang, Y, 2020) |
| " Apparent oral clearance and relative bioavailability for caffeine and S-warfarin were not significantly different between the subject populations." | 2.72 | Therapeutic Protein Drug Interaction Potential in Subjects With Psoriasis: An Assessment Based on Population Pharmacokinetic Analyses of Sensitive Cytochrome P450 Probe Substrates. ( Mohamed, MF; Othman, AA; Sathe, AG, 2021) |
| "Theophylline and caffeine were more potent than dyphylline." | 1.28 | Xanthines inhibit 3T3 fibroblast proliferation. ( Levi-Schaffer, F; Touitou, E, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (23.08) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 3 (23.08) | 2.80 |
| Authors | Studies |
|---|---|
| Zhu, Y | 1 |
| Xu, Y | 1 |
| Zhuang, Y | 1 |
| Piantone, A | 1 |
| Shu, C | 1 |
| Chen, D | 1 |
| Zhou, H | 1 |
| Xu, Z | 1 |
| Sharma, A | 1 |
| Iriventi, P | 1 |
| Gupta, NV | 1 |
| Osmani, RAM | 1 |
| Balamuralidhara, V | 1 |
| Sathe, AG | 1 |
| Othman, AA | 2 |
| Mohamed, MF | 1 |
| Khalilieh, S | 1 |
| Hussain, A | 1 |
| Montgomery, D | 1 |
| Levine, V | 1 |
| Shaw, PM | 1 |
| Bodrug, I | 1 |
| Mekokishvili, L | 1 |
| Bailey-Smith, C | 1 |
| Glasgow, XS | 1 |
| Cheng, A | 1 |
| Martinho, M | 1 |
| Iwamoto, M | 1 |
| Khatri, A | 1 |
| Cheng, L | 1 |
| Camez, A | 1 |
| Ignatenko, S | 1 |
| Pang, Y | 1 |
| Li, W | 1 |
| Han, J | 1 |
| Qureshi, AA | 1 |
| Vali, A | 1 |
| Asilian, A | 1 |
| Khalesi, E | 1 |
| Khoddami, L | 1 |
| Shahtalebi, M | 1 |
| Mohammady, M | 1 |
| Swanson, DL | 1 |
| Barnes, SA | 1 |
| Mengden Koon, SJ | 1 |
| el-Azhary, RA | 1 |
| Bendriss, EK | 1 |
| Bechtel, Y | 1 |
| Bendriss, A | 1 |
| Humbert, PH | 1 |
| Paintaud, G | 1 |
| Magnette, J | 1 |
| Agache, P | 1 |
| Bechtel, PR | 1 |
| Ippen, H | 1 |
| Kölmel, K | 1 |
| Levi-Schaffer, F | 1 |
| Touitou, E | 1 |
| Mays, DC | 1 |
| Camisa, C | 1 |
| Cheney, P | 1 |
| Pacula, CM | 1 |
| Nawoot, S | 1 |
| Gerber, N | 1 |
| Murad, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1, Open-label, Drug Interaction Study to Evaluate the Effect of Guselkumab (CNTO 1959) on Cytochrome P450 Enzyme Activities Following a Single Subcutaneous Administration in Subjects With Moderate to Severe Plaque-type Psoriasis[NCT02397382] | Phase 1 | 16 participants (Actual) | Interventional | 2015-06-18 | Completed | ||
| The Effect of Multiple Subcutaneous Doses of Risankizumab on the Single Dose Pharmacokinetics of Cytochrome P450 Substrates (Caffeine, Warfarin, Omeprazole, Metoprolol and Midazolam) Administered Orally in an Open-label, One-sequence Trial in Patients Wit[NCT02772601] | Phase 1 | 21 participants (Actual) | Interventional | 2016-09-15 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for caffeine and Palmoplantaris Pustulosis
| Article | Year |
|---|---|
Therapeutic Protein Drug Interaction Potential in Subjects With Psoriasis: An Assessment Based on Population Pharmacokinetic Analyses of Sensitive Cytochrome P450 Probe Substrates.
Topics: Adult; Biological Availability; Caffeine; Case-Control Studies; Cytochrome P-450 CYP1A2; Cytochrome | 2021 |
Clinical studies and applications of cyclic nucleotides.
Topics: Affective Symptoms; Animals; Asthma; Caffeine; Calcitonin; Calcium; Catecholamines; Circadian Rhythm | 1973 |
4 trials available for caffeine and Palmoplantaris Pustulosis
| Article | Year |
|---|---|
Evaluating Potential Disease-Mediated Protein-Drug Interactions in Patients With Moderate-to-Severe Plaque Psoriasis Receiving Subcutaneous Guselkumab.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Area Under Curve; Caffeine; Cytochrome P | 2020 |
Effect of tildrakizumab (MK-3222), a high affinity, selective anti-IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis.
Topics: Administration, Oral; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Caffeine; Cy | 2018 |
Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis.
Topics: Antibodies, Monoclonal; Area Under Curve; Caffeine; Chronic Disease; Cytochrome P-450 Enzyme System; | 2019 |
Evaluation of the efficacy of topical caffeine in the treatment of psoriasis vulgaris.
Topics: Administration, Topical; Adult; Caffeine; Double-Blind Method; Female; Humans; Male; Phosphodiestera | 2005 |
7 other studies available for caffeine and Palmoplantaris Pustulosis
| Article | Year |
|---|---|
Design & development of nanosponge loaded topical gel of curcumin and caffeine mixture for augmented treatment of psoriasis.
Topics: Administration, Topical; Animals; beta-Cyclodextrins; Caffeine; Curcumin; Delayed-Action Preparation | 2020 |
No association between coffee and caffeine intake and risk of psoriasis in US women.
Topics: Adult; Caffeine; Coffee; Cohort Studies; Cross-Sectional Studies; Female; Follow-Up Studies; Health | 2012 |
Caffeine consumption and methotrexate dosing requirement in psoriasis and psoriatic arthritis.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Psoriatic; Caffeine; Dermatologic Agents; Drug Interactio | 2007 |
Inhibition of caffeine metabolism by 5-methoxypsoralen in patients with psoriasis.
Topics: 5-Methoxypsoralen; Adult; Aged; Caffeine; Central Nervous System Stimulants; Female; Humans; Male; M | 1996 |
[Percutaneous caffeine poisoning (author's transl)].
Topics: Adult; Caffeine; Dermatitis, Exfoliative; Humans; Male; Psoriasis; Skin Absorption | 1977 |
Xanthines inhibit 3T3 fibroblast proliferation.
Topics: 3T3 Cells; Animals; Caffeine; Cell Division; Dyphylline; Mice; Psoriasis; Theophylline; Xanthines | 1991 |
Methoxsalen is a potent inhibitor of the metabolism of caffeine in humans.
Topics: Adult; Biotransformation; Caffeine; Female; Humans; Male; Metabolic Clearance Rate; Methoxsalen; Mid | 1987 |